25 September 2019

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

2019-09-25T15:17:16-07:00

*August 2019*  Science Immunology Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for rapidly killing

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity2019-09-25T15:17:16-07:00
12 August 2019

Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer

2019-08-12T16:26:24-07:00

*July 2019* The Oncologist. With the advent of immunotherapy, substantial progress has been made in improving outcomes for patients with

Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer2019-08-12T16:26:24-07:00